Latent Tuberculosis: Transmission, Diagnosis, Risk factors, recommendations

Latent Tuberculosis: Transmission, Diagnosis, Risk factors, recommendations  

Abstract:

 In 2017, 10.0 million new cases of Tuberculosis (TB) disease registered, which involved 5.8 million men, 3.2 million women and 1.0 million children. It’s a global health problem worldwide. In the same year 1.3 million deaths because of tuberculosis, which making it one of the top 10 causes of death and the leading cause from a single infectious agent.

About 1.7 billion people, 23% of the world’s population, are estimated to have a latent TB infection, and are thus at risk of developing active TB disease during their lifetime.

 Here, we review the transmission occurrence, the diagnosis and the risk factors of latent tuberculosis, to improve latent tuberculosis care globally.

Keywords: latent tuberculosis, transmission, diagnosis, Mycobacterium,

 

Introduction:

In 1882, the Mycobacterium tuberculosis (MTB) was discovered by Robert Koch. “all who mix with tuberculosis patient got infected, but remained well so long as they took care of themselves and kept the soil in condition unfavorable for the growth of the seed” written by William Osler in 1909[1].

In 2017, 10.0 million new instances of Tuberculosis (TB) malady enrolled, which included 5.8 million men, 3.2 million ladies, and 1.0 million youngsters. It's a worldwide medical issue. Around the same time 1.3 million passing in light of tuberculosis, which makes it one of the main 10 reasons for death and the main source of a solitary irresistible operator[2].

The start point of the tuberculosis epidemic is identified from the Latent Mycobacterium Tuberculosis infection (LTBI). Recently, the worldwide weight of M. Tuberculosis has been re-evaluated at 24%[3].

About 1.7 billion individuals, 23% of the total populace, are assessed to have an inactive TB contamination, and are in this way in danger of creating dynamic TB ailment amid their lifetime, as indicated by World Health Organization (WHO) [2].

The global rate of decline in tuberculosis incidence is currently 1.5% and will need to increase to 4% 5% by 2020 and then to 10% per year by 2025 to meet the World Health Organization End TB Strategy targets (Figure 1) [4]

Tuberculosis transmission: 

A simple cascade for tuberculosis transmission is proposed in which a source case of tuberculosis generates infectious particles, that survive in the air and are inhaled by a susceptible individual, who may become infected and who then has the potential to develop tuberculosis. Interventions that target bacterial, host, or behavioral catalysts of transmission will interrupt tuberculosis transmission and accelerate the decline in tuberculosis incidence and mortality[5]. Which summarize in 5 steps (Figure 02): 

ü  Step 01: source case

ü  Step 02: aerosolization

ü  Step 03: airborne survival

ü  Step 04: exposure and inhalation

ü  Step 05: infection

Who transmits the infection? 

The infectiousness of a person with tuberculosis is higher as well as the degree of smear positivity is increasing, which mean that the person with smear-positive pulmonary tuberculosis is highly infectious. In Peru, a large study compared the infectious risk in smear-positive and smear-negative household, this study showed that person with smear-positive has a higher risk of infectious, likewise, it found that there is a low risk of infection in smear-negative persons[6]. However, tuberculosis transmission can also be found in persons with smear-negative[7]. Coughing is the most efficiency infectious aerosols by shears the respiratory secretions which contain M, tuberculosis bacteria,  from the airways caused by a forced expiratory maneuver, compared with singing, sneezing, shouting or other respiratory symptoms[7].

Tuberculosis understanding who are tainted by HIV, particularly who are in cutting edge immunosuppression, they were accepted to have less probability at that point patient's HIV-uninfected with TB to transmit to family unit, presumably in view of a more noteworthy probability of having smear-negative tuberculosis and a shorter length of irresistibleness because of increasingly quick movement to death[8, 9].

Site of Transmission occurrence 

In 1905, Robert Koch said in his Nobel Lecture: “tuberculosis has been called plainly, and quite justly, a disease of accommodation”[10].

When the age of the household contact is less than 15 years and the index cases are smear-positive, the tuberculosis transmission to them is most probably happened[6, 11]. 

In addition, in high TB burden, in mines, workplaces, schools, public transportation, and healthcare facilities, tuberculosis transmission is therefore likely to occur outside the household[9, 11-18]. 

Person risk 

In low and middle incomes countries; within 95 contact investigation studies, the M. tuberculosis prevalence was 51.5% among contacts. Moreover, the higher risk of tuberculosis infection is HIV patients and who is <5 years old[19].

Accordingly, the closer contacts with TB patients the more risk to be infected is higher, which leads to progress the TB, especially in the first years of exposure, when the infection happens. [19]

To identify persons with a higher risk of developing TB, the medical history of the person or a simple test is required[5].  

Tuberculosis diagnosis 

Tuberculosis skin test 

TST is at present still the most generally utilized and accessible test for the analysis of tuberculous contamination. Following disease with Mycobacterium tuberculosis, a course of insusceptible reactions results activated by initiated macrophages and completed by T cells. Two distinctive cell-intervened insusceptibility systems result in the two assurances, interceded byTh1 cytokines (interleukin 2, interleukin 12, and gamma interferon [IFN-γ]), and postponed type excessive touchiness, intervened by chemokines[20].

Contamination with M. tuberculosis results in a deferred sort excessive touchiness response to antigens got from the life form, which is the premise of the TST. Legitimate utilization of the TST requires information of the antigen utilized, the immunologic reason for the response to this antigen, the correct procedure of overseeing and perusing the test, and the consequences of epidemiological and clinical involvement with the test. At the point when the material is infused intradermally, an exemplary deferred extreme touchiness response happens in the tainted patient. The underlying procedure of sharpening following contamination takes around 6 to about two months, with sharpened T lymphocytes creating in territorial lymph hubs and entering the dissemination. incitement of these lymphocytes by intracutaneous infusion of tuberculin results in the indurated skin response of a positive outcome. The induration is because of cell infiltration interceded by the sharpened lymphocytes. Thereactionismaximalat48to 72 h and after that gradually blurs, in spite of the fact that it usually goes on for in excess of 96 h. Two sorts of tuberculin arrangements have been being used, old tuberculin (OT) and purified protein subordinate (PPD)[20, 21].

TUBERCULIN—HISTORICAL PERSPECTIVE 

Tuberculin was built up 10 years after Robert Koch found the tubercle bacillus and furthermore a technique for developing it in unadulterated culture in 1882. He thought of this readiness from warmth disinfected societies of tubercle bacilli that were filtered and focused and contained tuberculous proteins. It was at first utilized and touted as restorative. In any case, the healing estimation of the readiness was frustrating; in any case, it prompted the disclosure of tuberculin's analytic esteem. Since the first arrangement, known as OT (old tuberculin), was an unrefined item with the unessential material present, a positive response came up short on the affectability to be demonstrative of disease with M. tuberculosis. OT was accessible for various cut tests[21]. 

PURIFIED PROTEIN DERIVATIVE PPD 

was initially created by Florence Siebert in 1939 at the Phipps Institute in Philadelphia, PA. It is an encourage arranged from filtrates of OT with ammonium sulfate or trichloroacetic corrosive. The reference standard material for all tuberculin is PPD-S. In 1972, the Bureau of Biologics of the Food and Drug Administration ordered that the standard test portion of all Tween-containing PPD tuberculin authorized for use in people be naturally comparable to 5 tuberculin units (TU) of PPD-S[21, 22].

The definition of tuberculous infectionisapositivereactionto5TU of PPD[22]. Tween 80 is added to the PPD diluent to keep antigenic material from being consumed by the glass and plastic holders and syringes, in this manner anticipating diminished strength of the planning. PPD antigen is controlled by different cut tests and by the intradermal Mantoux test. Various cut and PPD qualities of 1 and 250 TU are not exact and are never again utilized.

MANTOUX TEST 

The Mantoux test is performed by intradermally infusing 0.1 ml of PPD tuberculin (5 TU) into the skin of the volar part of the lower arm. A solitary portion plastic syringe is utilized with a 26-to 27-check needle. The infusion is finished with the needle slant upward. An unmistakable wheal 6 to 10 mm in breadth should result. The best possible portion is significant; the bigger the portion, the bigger the response. Flimsier dosages produce littler responses. The test is perused in 48 to 72 h[21].

Test significance relies upon the nearness or nonappearance of induration. The nearness of induration is controlled by contact. The distance across of the induration is estimated transversely. Erythema isn't considered. The span of induration (in millimeters), the antigen quality and parcel number, the date of testing, and the date of perusing are altogether recorded. Unfavorable responses to PPD are strange. Some delicate people may create nearby ulceration or vesicle arrangement. Fever and lymphadenopathy may likewise happen. Beside neighborhood wound consideration, no specific treatment is shown in these examples[21]. 

A new concept of Latent tuberculosis diagnosis 

More broadly available methods for the detection of LTBI include the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA)[23].

although generally the IGRA is reported to yield results of higher specificity because of the use of antigens which are specific to M. tb[24]. The TST, which utilizes antigens shared across mycobacterial species, suffers from relatively low specificity because of the false-positive response. of individuals who have been exposed to environmental mycobacteria or the BCG vaccine [23].

Araujo et al. [25] recently explored the response of newly infected individuals to several
latency-associated antigens (LAA) over the course of a year, garnering some insights into which host responses may portend progression to active disease. T-cell responsiveness to heparin-binding hemagglutinin (HBHA) has been proposed to predict reactivation risk[26]. In an HIV-positive population, T-cell response to HBHA was negatively correlated with reactivation[27], confirming that a positive T-cell response to HBHA may indicate that a patient will continue to contain the disease.

De Groote et al.[28] also found higher levels of granzyme B in the blood of LTBI patients,
highlighting the importance of the adaptive immune system in the maintenance of LTBI and pointing to granzyme B as a possible indicator of reduced reactivation risk. 

Risk factors of Tuberculosis: 

HIV coinfection: 

Known as the most strong risk factor of reactivation for TB[29]. According to different studies, HIV infection might lead from 10 to 100 times higher risk of LTB infection reactivation[30-32].

In 2019, the WHO rules on tuberculosis contamination aversion and control demonstrated the significance of LTBI treatment in HIV patients in both low-and high-pay nations [33].

Along these lines, the WHO suggested that all HIV patients who have obscure or positive screening test results and have no proof of dynamic TB get prophylaxis, despite the fact that patients with a positive TST or IGRA result may profit more from preventive treatment. For HIV patients with negative screening test results, doctors ought to assess their individual TB hazards and choose whether treatment ought to be recommended[34]. 

Diabetes mellitus 

Patients who diagnosed with diabetes mellitus (DM) have a higher risk to get an infection from latent to active tuberculosis[35]. 15% of tuberculosis patient might be linked to DM.

WHO collaborative framework for TB and DM recommended bidirectional screening-screening for both all patient who have Tuberculosis or diabetes mellitus[36].

A study of DM patients gives a result that when the hemoglobin A1c (HbA1c) level is greater or equal 7% the risk of active tuberculosis is three times more than those who have HbA1c less the 7%[37]. Night sweats, dyspnea, fever, and weight loss are the clinical symptoms in a patient who have DM[37]. Even the patient who use insulin more the 40 units have a higher risk for TB more than patients use less does. 

Usually, female, older and obese consider as TB patient and diagnosed previously from DM. In the opposite, patients with TB and newly-diagnosed DM are male and younger, as well as to have a lower level of HbA1c[38].

Smoking 

Tuberculosis rates are higher in underdeveloped or developing countries, where from 1.3 billion tobacco consumer worldwide live[39].

Regarding smoking role in tuberculosis pathogenesis, have a relation to reduced immune response, to ciliary dysfunction and to defects in the immune response of macrophage rising the M. tuberculosis infection[39]. Death due TB is nine times higher in smokers compared to never use tobacco in his life[40].

In 2017, a prospective study in rural China, confirm that smoking is important to risk factor especially in old smokers for tuberculosis infection, as well as give strong evidence of the relation between persons who have smoking history and the risk of talent tuberculosis[41].

Ongoing examinations recommend that in the recognition of idle tuberculosis with IFN-γ strategies, the extent of false-negative outcomes is higher among smokers than among nonsmokers, and that smoking negatively affects the aftereffects of tuberculosis treatment[42].

Drink of Alcohol 

Worldwide, alcohol consumption is a normal habit, which could be addictive to many people. Alcohol is considered as one of the top 5 risk factors of different diseases and death. It has been a causal factor in more than 200 diseases in the world[32]. From tuberculosis cases, about 10% are related to alcohol[43].

A partner of people experiencing liquor use issue was pursued for a long time, In a planned report in New York City, demonstrated that the occurrence of tuberculosis is multiple times the frequency analyzed the age-coordinated all-inclusive community[44].

in China, a prospective cohort study of adults followed for 16.8 ± 5.2 years[45]. The result showed the association between the alcohol consumption and the rising of tuberculosis risk, which is more have a more higher risk when alcohol (≥ 2 drinks per day) and smoking are combined together[46]. 

Illegal Drug Use 

The relationship between illegal drug use and tuberculosis is increasing according to the epidemiological data, because of the human, economic, social and political aspect it leads to a public health problem[47].

The utilization of powder or rocks was found, in two separate studies [48, 49], to be connected legitimately with the predominance of dynamic and inactive tuberculosis; delays in the higher rates of retreatment; and the development of multidrug-safe strains; conclusion of the malady; resistance with and surrender of treatment.

In the US, an investigation of 147 inpatients which finding of mental sicknesses, demonstrated that the utilization of rocks has an association with a positive PPD skin test. The hazard in medication clients is higher contrasted and non-tranquilize clients[50].

There is a big need from the health professions and the governments around the world to create new strategies and new policy to control the drug user in the society, because of the increasing of drug users in many countries, which is correlated with tuberculosis infection disease[35].  

Latent Tuberculosis Infection recommendations 

 

Close contact TB 

Population who had a close contact with drug-susceptible TB infection patients ought to be testing and treatment should be given as a priority, due to probability of an early progression of the disease maybe observed. Moreover, more priority must be applied for the child when a TB patient contact happened[51].

Risk of sever form of the dieses might be increase particularly in those who are under five years old. The lethal epidemic on the generic screen has proven to be a reliable, non-tuberculosis ant tuberculous treatment prior to conventional treatment[52].

Given the logistical barriers to the use of TST in restricted pores and excellent resistance to pediatric prophylaxis, an experimental treatment may be useful for newly established young children. For children the effective treatment involves the same adult LTBI antibiotics, with a dose-adjusted dose based on weight[53].

The most important contact group recommended from WHO for treatment is children under 5 years of age and HIV-infected people, given their susceptibility to the development of serious diseases. However, these guidelines recognize the importance of providing preventive care for all infected persons, regardless of age or associated diseases, as far as possible[51].

New migrants 

In areas of low prevalence, most tuberculosis is common among newly arrived immigrants in the affected area. To significantly reduce tuberculosis in such an environment, you must prevent infection of infected immigrants with tuberculosis. Preventive testing for active tuberculosis is carried out in many environments, including the United States, Europe, Australia and Canada. However, until recently, testing for LTBI was not recommended. The CDC concluded that it would provide corresponding net economic benefits if screening of individuals in selected countries at high risk for LTBI would be possible[54]. In the UK, new immigrants under the age of 35 are selected in countries with a TB incidence of 150/100 000[55].

This policy is based on the assumption that the toxicity of treatment will be relatively small compared with the long-term interests of individuals and groups of the population. Recognizing that most local displacement occurs between recent immigrants; this reflects growth momentum for comprehensive testing and treatment of LTI in resource-rich countries[56].

Ultimately, eradicating tuberculosis in countries with low prevalence and large numbers of immigrants will aggressively reduce tuberculosis outbreaks in high-burden countries[57, 58].

Immunocompromised 

The risk of the resumption of tuberculosis is increased in people with immunosuppressive conditions, such as poorly controlled diabetes mellitus[59], chronic renal failure[60], , or treatment with tumor necrosis factor (TNF) inhibitors[61].

These risk factors for medical factors should be taken into account when assessing the risk ratio and the winning factor of a particular patient with LTBI. Modeling analysis of the solution has shown that most immune damage to patients benefits from the LTBI treatment[62].

However, there are some additional factors that should be considered as a solution for determining the condition of the immune system depression. In some populations, the accuracy of the prevalence and MTBN test of LTTBI (especially the ratio of false-negative results of TSTs and IGRAs) will have a significant effect on the cost and benefit of the screening program[57].

 Full Text

References

1.            TE Dobbs, M.K., AIDS Therapy E-Book. . 2008, PA: Elsevier: Philadelphia.

2.            WHO, Global tuberculosis reporte 2018. 2018, France: Paris.

3.            Houben, R.M. and P.J. Dodd, The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016. 13(10): p. e1002152.

4.            Churchyard, G., et al., What We Know About Tuberculosis Transmission: An Overview. J Infect Dis, 2017. 216(suppl_6): p. S629-s635.

5.            Dowdy, D.W., et al., Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin Infect Dis, 2014. 59(8): p. 1123-9.

6.            Zelner, J.L., et al., Age-specific risks of tuberculosis infection from household and community exposures and opportunities for interventions in a high-burden setting. Am J Epidemiol, 2014. 180(8): p. 853-61.

7.            Turner, R.D. and G.H. Bothamley, Cough and the transmission of tuberculosis. J Infect Dis, 2015. 211(9): p. 1367-72.

8.            Huang, C.C., et al., The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect Dis, 2014. 58(6): p. 765-74.

9.            Corbett, E.L., et al., Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med, 2007. 4(1): p. e22.

10.          Koch, R., The Nobel Prize, in Nobel Lecture. 2014, Stockholm, Sweden: Nobel Media.

11.          Andrews, J.R., et al., Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. J Infect Dis, 2014. 210(4): p. 597-603.

12.          Andrews, J.R., C. Morrow, and R. Wood, Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa. Am J Epidemiol, 2013. 177(6): p. 556-61.

13.          Yates, T.A., et al., The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infect Dis, 2016. 16(2): p. 227-38.

14.          Churchyard, G.J., et al., A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med, 2014. 370(4): p. 301-10.

15.          Telisinghe, L., et al., High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS One, 2014. 9(1): p. e87262.

16.          Johnstone-Robertson, S., et al., Tuberculosis in a South African prison - a transmission modelling analysis. S Afr Med J, 2011. 101(11): p. 809-13.

17.          Escombe, A.R., et al., Tuberculosis transmission risk and infection control in a hospital emergency department in Lima, Peru. Int J Tuberc Lung Dis, 2010. 14(9): p. 1120-6.

18.          Escombe, A.R., et al., Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med, 2009. 6(3): p. e43.

19.          Fox, G.J., et al., Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2013. 41(1): p. 140-56.

20.          Orme, I.M. and A.M. Cooper, Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today, 1999. 20(7): p. 307-12.

21.          Lardizabal, A.A. and L.B. Reichman, Diagnosis of Latent Tuberculosis Infection. Microbiol Spectr, 2017. 5(1).

22.          American Thoracic Society. Diagnostic standards and classification of tuberculosis and other mycobacterial diseases (14th edition). Am Rev Respir Dis, 1981. 123(3): p. 343-58.

23.          Mazurek, G.H., et al., Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep, 2010. 59(Rr-5): p. 1-25.

24.          Pai, M. and M. Behr, Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiol Spectr, 2016. 4(5).

25.          de Araujo, L.S., et al., Profile of interferon-gamma response to latency-associated and novel in vivo expressed antigens in a cohort of subjects recently exposed to Mycobacterium tuberculosis. Tuberculosis, 2015. 95(6): p. 751-757.

26.          Immunological Signatures Identifying Different Stages of Latent Mycobacterium tuberculosis Infection and Discriminating Latent from Active Tuberculosis in Humans. 2015. 6(341).

27.          Delogu, G., et al., Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. Scand J Immunol, 2016. 84(6): p. 344-352.

28.          De Groote, M.A., et al., Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. J Clin Microbiol, 2017. 55(2): p. 391-402.

29.          Antonucci, G., et al., Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Jama, 1995. 274(2): p. 143-8.

30.          Horsburgh, C.R., Jr. and E.J. Rubin, Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med, 2011. 364(15): p. 1441-8.

31.          Landry, J. and D. Menzies, Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis, 2008. 12(12): p. 1352-64.

32.          WHO, GLOBAL HEALTH RISKS: Mortality and burden of disease attributable to selected major risks. 2009, Switzerland: Geneva.

33.          WHO, WHO guidelines on tuberculosis infection prevention and control. 2019, World Health organization: Geneva.

34.          WHO, World Health Organization. 2019.

35.          Silva, D.R., et al., Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol, 2018. 44(2): p. 145-152.

36.          Pizzol, D., et al., Tuberculosis and diabetes: current state and future perspectives. Trop Med Int Health, 2016. 21(6): p. 694-702.

37.          Dooley, K.E. and R.E. Chaisson, Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis, 2009. 9(12): p. 737-46.

38.          Restrepo, B.I., Diabetes and Tuberculosis. Microbiol Spectr, 2016. 4(6).

39.          van Zyl Smit, R.N., et al., Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J, 2010. 35(1): p. 27-33.

40.          Wen, C.P., et al., The reduction of tuberculosis risks by smoking cessation. BMC Infect Dis, 2010. 10: p. 156.

41.          Zhang, H., et al., A dose-response relationship of smoking with tuberculosis infection: A cross-sectional study among 21008 rural residents in China. PLoS One, 2017. 12(4): p. e0175183.

42.          Altet, N., et al., Assessment of the influence of direct tobacco smoke on infection and active TB management. PLoS One, 2017. 12(8): p. e0182998.

43.          Rehm, J., et al., The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health, 2009. 9: p. 450.

44.          Friedman, L.N., et al., Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N Engl J Med, 1996. 334(13): p. 828-33.

45.          Soh, A.Z., et al., Alcohol drinking and cigarette smoking in relation to risk of active tuberculosis: prospective cohort study. BMJ Open Respir Res, 2017. 4(1): p. e000247.

46.          Hermosilla, S., et al., Identifying risk factors associated with smear positivity of pulmonary tuberculosis in Kazakhstan. PLoS One, 2017. 12(3): p. e0172942.

47.          Deiss, R.G., T.C. Rodwell, and R.S. Garfein, Tuberculosis and illicit drug use: review and update. Clin Infect Dis, 2009. 48(1): p. 72-82.

48.          Paixao, L.M. and E.D. Gontijo, [Profile of notified tuberculosis cases and factors associated with treatment dropout]. Rev Saude Publica, 2007. 41(2): p. 205-13.

49.          Rodrigues, I.L., et al., [Abandonment of tuberculosis treatment among patients co-infected with TB/HIV]. Rev Esc Enferm USP, 2010. 44(2): p. 383-7.

50.          Taubes, T., et al., Crack cocaine and schizophrenia as risk factors for PPD reactivity in the dually diagnosed. J Addict Dis, 1998. 17(3): p. 63-74.

51.          World Health Organisation, in Guidelines on the management of latent tuberculosis infection. 2015, WHO.

52.          Triasih, R., et al., A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis, 2015. 60(1): p. 12-8.

53.          Marais, B.J., et al., Screening and preventive therapy for tuberculosis. Clin Chest Med, 2009. 30(4): p. 827-46, x.

54.          Bibbins-Domingo, K., et al., Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. Jama, 2016. 316(9): p. 962-9.

55.          Pareek, M., et al., Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis, 2011. 11(6): p. 435-44.

56.          McBryde, E.S. and J.T. Denholm, Risk of active tuberculosis in immigrants: effects of age, region of origin and time since arrival in a low-exposure setting. Med J Aust, 2012. 197(8): p. 458-61.

57.          Fox, G.J., et al., Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis, 2017. 56: p. 68-76.

58.          Denholm, J.T., E.S. McBryde, and G.V. Brown, Ethical evaluation of immigration screening policy for latent tuberculosis infection. Australian and New Zealand Journal of Public Health, 2012. 36(4): p. 325-328.

59.          Dobler, C.C., J.R. Flack, and G.B. Marks, Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open, 2012. 2(1): p. e000666.

60.          Dobler, C.C., S.P. McDonald, and G.B. Marks, Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One, 2011. 6(12): p. e29563.

61.          Solovic, I., et al., The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J, 2010. 36(5): p. 1185-206.

62.          Dobler, C.C., A. Martin, and G.B. Marks, Benefit of treatment of latent tuberculosis infection in individual patients. Eur Respir J, 2015. 46(5): p. 1397-406.